PMID: 8980778Jan 1, 1997Paper

Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis

Antimicrobial Agents and Chemotherapy
F G AraujoJ S Remington

Abstract

The capacity of interleukin 12 (IL-12) to potentiate drugs in the treatment of murine toxoplasmosis was examined. IL-12 (100 ng/injection), atovaquone (10 mg/kg of body weight/day), or clindamycin (5 mg/kg/day) administered alone caused delayed time to death or minimal survival rates. In contrast, significant survival rates resulted when the same dose of IL-12 was used in combination the same doses of atovaquone (P=0.01) or clindamycin (P=0.001). Infected mice treated with IL-12 plus drug produced significantly higher levels of gamma interferon than controls. Although IL-12 was effective only when administered before infection, these results suggest that this cytokine may be a useful adjunct in the therapy of human toxoplasmosis in situations when cysts reactivate and tachyzoites start multiplying in immunocompromised patients.

References

Aug 1, 1991·Antimicrobial Agents and Chemotherapy·F G Araujo, J S Remington
May 1, 1990·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·D Israelski, J Remington
May 1, 1994·Infection and Immunity·I A KhanL H Kasper
Oct 1, 1994·Immunology Today·G Trinchieri, P Scott
Jul 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·R T GazzinelliA Sher
Mar 1, 1994·Antimicrobial Agents and Chemotherapy·F G AraujoJ S Remington
Jun 1, 1974·Antimicrobial Agents and Chemotherapy·F G Araujo, J S Remington

❮ Previous
Next ❯

Citations

Aug 1, 1997·Expert Opinion on Investigational Drugs·J A Carr, M J Mulqueen
Dec 22, 2020·International Journal for Parasitology·Nicholas C SmithGiel G van Dooren

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.